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Vaccination with NS1-Truncated H3N2 Swine Influenza Virus Primes T
Cells and Confers Cross-Protection against an H1N1 Heterosubtypic
Challenge in Pigs
Abstract
The diversity of contemporary swine influenza virus (SIV) strains impedes effective immunization of swine
herds. Mucosally delivered, attenuated virus vaccines are one approach with potential to provide broad cross-
protection. Reverse genetics-derived H3N2 SIV virus with truncated NS1 (NS1Δ126 TX98) is attenuated
and immunogenic when delivered intranasally in young pigs. We analyzed T-cell priming and cross-protective
efficacy in weanling piglets after intranasal inoculation with NS1Δ126 TX98 versus wild type TX98. In vivo
replication of the truncation mutant was minimal compared to the wild type virus. T-cell responses were
greater in magnitude in pigs infected with the wild type virus in in vitro restimulation assays. According to the
expression of activation marker CD25, peripheral T cell recall responses in NS1Δ126 TX98 infected pigs were
minimal. However, intracellular IFN-γ data indicate that the attenuated virus induced virus-specific
CD4+CD8–, CD4+CD8+, CD4–CD8+, and γδ T cells within 28 days. The IFN-γ response appeared to
contract, as responses were reduced at later time points prior to challenge. CD4+CD8+ cells isolated 5 days
after heterosubtypic H1N1 challenge (day 70 overall) showed an elevated CD25 response to virus
restimulation. Pigs previously infected with wild type TX98 were protected from replication of the H1N1
challenge virus. Vaccination with NS1Δ126 TX98 was associated with significantly lower levels of
Th1-associated cytokines in infected lungs but provided partial cross-protection against the H1N1 challenge.
These results demonstrate that NS1Δ SIV vaccines can elicit cell-mediated cross-protection against
antigenically divergent strains.
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a  b  s  t  r  a  c  t
The  diversity  of  contemporary  swine  inﬂuenza  virus  (SIV)  strains  impedes  effective  immunization  of
swine  herds.  Mucosally  delivered,  attenuated  virus  vaccines  are  one  approach  with  potential  to provide
broad cross-protection.  Reverse  genetics-derived  H3N2  SIV  virus  with  truncated  NS1  (NS1126  TX98)
is  attenuated  and  immunogenic  when  delivered  intranasally  in young  pigs.  We  analyzed  T-cell priming
and  cross-protective  efﬁcacy  in weanling  piglets  after  intranasal  inoculation  with  NS1126  TX98  versus
wild  type  TX98.  In  vivo  replication  of  the  truncation  mutant  was  minimal  compared  to  the wild  type
virus.  T-cell  responses  were  greater  in  magnitude  in  pigs  infected  with  the  wild  type  virus  in  in vitro
restimulation  assays.  According  to  the  expression  of  activation  marker  CD25,  peripheral  T  cell  recall
responses  in  NS1126  TX98  infected  pigs  were  minimal.  However,  intracellular  IFN-  data  indicate
that  the attenuated  virus  induced  virus-speciﬁc  CD4+CD8–, CD4+CD8+, CD4–CD8+, and    T cells  within
28  days.  The  IFN-  response  appeared  to  contract,  as  responses  were  reduced  at  later  time  points  prior  to
challenge.  CD4+CD8+ cells  isolated  5  days  after  heterosubtypic  H1N1  challenge  (day  70 overall)  showed
an  elevated  CD25  response  to  virus  restimulation.  Pigs  previously  infected  with  wild  type  TX98  were
protected  from  replication  of  the  H1N1  challenge  virus.  Vaccination  with  NS1126  TX98  was  associated
with  signiﬁcantly  lower  levels  of  Th1-associated  cytokines  in  infected  lungs  but provided  partial  cross-
protection  against  the  H1N1  challenge.  These  results  demonstrate  that  NS1  SIV  vaccines  can  elicit
cell-mediated  cross-protection  against  antigenically  divergent  strains.
Published by Elsevier Ltd.
1. Introduction
Pigs have been recognized as a natural host of inﬂuenza A
virus since the virus was ﬁrst isolated in 1930. After a relatively
slow evolution of classical H1N1 swine inﬂuenza virus (SIV) in the
North American swine population, a new reassortant H3N2 lin-
eage emerged and was established around 1998 [1].  Compared to
the classical swine H1N1, this SIV lineage has shown a propen-
sity for frequent gene reassortment and rapid antigenic drift [2–5].
Variants of this reassortant lineage, which have been isolated rou-
tinely in recent years, possess H3N2, H1N1, and H1N2 serotypes
(reviewed by Vincent et al. [6]). Segments of the “triple reassortant
internal gene” (TRIG) cassette were acquired from swine, avian,
and human inﬂuenza A lineages [1].  Occasional reassortants have
∗ Corresponding author: Tel.: +1 515 337 7254.
E-mail address: marcus.kehrli@ars.usda.gov (M.E. Kehrli Jr.).
1 These authors contributed equally to the study.
emerged in swine with novel surface glycoproteins with the TRIG
[5,7]. Five of the six gene segments which encode internal proteins
in the 2009 pandemic H1N1 virus were derived from this North
American TRIG lineage [8]. The emergence of this virus illustrates
the risk to public health as inﬂuenza A virus genes of diverse origins
are shufﬂed together in the backbone of the mammalian-adapted
triple reassortant virus.
Additional antigenically distinct reassortant viruses could
potentially emerge from swine lineages into the human population
[9]. New variants may  also have great economic costs to the swine
industry. Therefore, there is a strong rationale for investigations
into the immunological relationships among recent and emerg-
ing subtypes or genotypes of swine-origin reassortant inﬂuenza
viruses. Experimental evaluation of modern vaccine technology for
SIV in the swine host is important for achieving greater control
of the various strains in swine populations and limiting the risk
of transmission to humans. The antigenic diversity of inﬂuenza
viruses circulating and becoming established in global swine popu-
lations suggests that veterinary vaccination programs are unlikely
0264-410X/$ – see front matter Published by Elsevier Ltd.
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to produce neutralizing humoral immunity against all emerg-
ing strains. Therefore, an important consideration in evaluating
candidate vaccines should be the degree to which they elicit cross-
reactive cell-mediated immunity. Although inﬂuenza-speciﬁc T
cells do not provide sterilizing immunity, they protect more broadly
than neutralizing antibodies against heterologous and heterosub-
typic strains through viral clearance [10,11].  Broadly cross-reactive
T cell epitopes are typically located in internal proteins of inﬂuenza
viruses such as the nucleoprotein (NP) and matrix (M1) segments,
which are more conserved than the surface hemagglutinin (HA)
and NA glycoproteins [12–14].  Cellular immunity to inﬂuenza in
the absence of cross-reactive antibody can markedly reduce viral
replication in humans and pigs [15,16].
Live virus vaccines are considered to be more effective than
inactivated or non-replicating vaccines as inducers of cellular
immunity, particularly for MHC  class I-restricted T cells, but all
licensed SIV vaccines in the US are based on inactivated virus anti-
gens. Molecular approaches have been used to construct mutated
SIV genomes which confer attenuated replication properties,
including reduced NS1 suppression of type I interferon, dependence
on the enzyme elastase for HA cleavage, and temperature-sensitive
mutations in polymerase genes [17–19].  Truncation of NS1 pro-
tein in triple reassortant H3N2 strain A/Sw/Texas/4199-2/98, from
a length of 230 amino acids to 126, produced a mutant with
restricted replication in the swine respiratory tract but strong
immunogenic properties [20]. Intranasal inoculation of pigs with
this virus (NS1126 TX98) resulted in robust protection against
homologous challenge and signiﬁcantly reduced viral replication
and clinical signs upon challenge with a drift variant strain [21].
One likely factor in the partial heterologous protection was  the
production of mucosal IgA antibodies that had signiﬁcant cross-
reactivity against the drift variant. No investigation was made into
the priming of T cells subsets in the NS1126 TX98 immunized
pigs, but we hypothesize that cross-protection was  mediated at
least in part by the cell-mediated immune (CMI) response. A theo-
retical concern with live SIV vaccines, such as NS1126 TX98, is the
possibility that they would undergo reassortment with circulating
strains and produce variants with altered virulence, transmissibil-
ity, or host range. This vaccine does not possess any novel genetic
elements to contribute to the current circulating pool of inﬂuenza
viruses as the parental H3N2 TRIG background from which the
NS1126 TX98 vaccine strain was generated continues to circu-
late widely in the US swine population, and therefore concerns
about the swine host acting as a mixing vessel in this context
should be minimal [6].  Attenuated H1N1 SIVs made by intro-
ducing elastase dependent mutations also protected pigs against
homologous and heterologous H1N1 challenge while eliciting sig-
niﬁcant T-cell responses and lung IgA titers against both strains
[22].
In the present investigation we analyzed the CMI  response fol-
lowing NS1126 TX98 or wild type virus vaccination by measuring
ex vivo responses of each major T cell subset from vaccinated or
unvaccinated pigs to attenuated or wild-type virus. Serum and
peripheral blood mononuclear cells (PBMC) were collected at mul-
tiple time points following vaccination, the last of which was  5 days
after heterologous H1N1 virus challenge. The heterologous chal-
lenge virus was a reassortant H1N1 (rH1N1) subtype isolated after
classical swine H1N1 surface glycoproteins reassorted with H3N2
SIV [23]. The heterosubtypic challenge strain carries the TRIG cas-
sette, which is common to the TX98-derived vaccine candidates
(Supplemental Table 1). Immunization with either attenuated or
wild type virus elicited antigen-speciﬁc responses by peripheral T
cells. After heterologous challenge of the immunized animals, T-
cell sensitivity to viral stimulation was augmented again in both
groups, but the phenotypic characteristics of responding cells were
shifted markedly.
2. Materials and methods
2.1. Viruses
The H3N2 isolate A/swine/Texas/4199-2/1998 (TX98) was prop-
agated in allantoic cavities of 10-day old embryonated chicken eggs
to produce an inoculum for vaccination. To limit recall responses
to non-viral endogenous egg antigens, the IA04 H1N1 challenge
viral stock was  propagated in Madin-Darby canine kidney (MDCK)
cells. The same strains were grown in MDCK cell cultures to gener-
ate recall antigen for ex vivo stimulation of T cells. Live inﬂuenza A
virus NS1126 TX98 was generated by reverse genetics, as previ-
ously described [17], and propagated in allantoic cavities of 10-day
old embryonated chicken eggs to produce an inoculum for vaccina-
tion. Sequences of IA04 were generated by 454 genome sequencing
technology, complemented by Sanger sequencing to ﬁll gaps, as
described previously [24]. Sequence data covering portions of each
TX98 gene segment were accessed from the NCBI database.
2.2. Experimental design
Twenty-four three-week old pigs were treated with ceftiofur
crystalline antibiotic (EXCEDETM, Pharmacia & Upjohn Company)
per manufacturer’s recommended dose and randomly separated
into groups of eight pigs to be housed for 1 week prior to immuniza-
tion. All pigs were conﬁrmed seronegative for SIV by hemagglutina-
tion inhibition (HI) assays against H1N1 and H3N2 antigens and free
from detectable inﬂuenza infection by virus isolation from nasal
swabs collected on the day of vaccination. At day 0, inocula were
prepared by dilution in sterile phosphate buffered saline (PBS) and
administered intranasally by slowly dripping 2 ml  into the nasal
cavity of each pig. Pigs in the non-vaccinated group received an
intranasal sham inoculation. The second group received NS1126
TX98 at a 50% tissue culture infectious dose (TCID50) of 106 per ml.
The third group received wild type TX98 at a dose of 106 TCID50/ml.
At day 65 post vaccination (dpv), all subjects were challenged with
the wild type H1N1 inﬂuenza strain IA04 at a dose of 106 TCID50/ml.
Pigs were observed for clinical signs for 5 days after challenge. Nasal
swabs were obtained 0, 2, 4, 6, 65, 68, 70 dpv and serum samples
were collected 0, 14, 28, 49, 56, 65, 70 dpv. Anticoagulated whole
blood for isolation of mononuclear cells to assess CMI was collected
28, 49, 56, and 70 dpv. Pigs were euthanized and necropsied 5 days
post challenge. Bronchoalveolar lavage ﬂuid (BALF) was collected
for virus titration as described previously, using 50 ml Minimum
Essential Medium per lung lavage [21]. Viral titers were analyzed in
nasal swab and BALF samples by a standard tissue culture infectious
dose assay on MDCK cell monolayers. Fifty percent endpoint titers
were computed by the Reed–Meunch method [25]. The presence of
macroscopic lung lesions for all seven lung lobes was  examined and
scored as previously described [26]. All animal studies were con-
ducted in accordance with the National Animal Disease Center’s
Institutional Animal Care and Use Committee.
2.3. Serology
Serum samples were heat inactivated at 56 ◦C for 30 min  and
treated with a 20% kaolin suspension (Sigma–Aldrich, St. Louis, MO)
for 30 min, followed by adsorption with 0.5% turkey red blood cells
to remove nonspeciﬁc agglutinins. HI tests were performed with
0.5% turkey red blood cells and MDCK-propagated TX98 virus, using
standard techniques [27].
2.4. Histopathology
Sections of lung tissue were collected from each animal and
ﬁxed in a 4% buffered formalin solution at time of necropsy for
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histopathologic examination. A pathologist blinded to the study
scored all tissues. Lung sections were examined for the percent-
age of airways with lesions, percentage of airways with epithelial
changes, and percentage of airways with inﬂammation (1 = 0–25%,
2 = 26–50%, 3 = 51–75%, 4 = 76–100%); severity of airway epithe-
lial changes (0 = none, 1 = early, 2 = mild, 3 = moderate, 4 = severe);
interstitial pneumonia (0 = none, 1 = mild, 2 = moderate, locally
extensive, 3 = moderate, multifocal to coalescing, 4 = severe); as
well as edema and neutrophilic inﬁltration (0 = none, 1 = mild,
2 = moderate, 3 = severe). Epithelial changes graded on a 5-point
scale were as follows: 0, no lesions; 1, early epithelial changes
characterized by focal to multifocal loss of cilia and epithelial
degenerative changes; 2, mild epithelial ﬂattening with loss of cilia
and goblet cells; 3, moderate epithelial ﬂattening with decreased
thickness of respiratory epithelium, loss of cilia and goblet cells; 4,
ﬂattened epithelium with areas of mucosa covered by a single layer
of cuboidal epithelium and epithelial loss (necrosis). Mean scores
across all parameters were calculated for each pig.
2.5. Inﬂuenza-speciﬁc isotype ELISA
Inﬂuenza antigen and isotype-speciﬁc ELISAs were performed
as previously reported [3].  Brieﬂy, TX98 and IA04 virus super-
natants were puriﬁed by ultracentrifugation and diluted to 100 HA
units/50 L. Immulon-2 96-well plates were coated with 200 HA
units per well overnight at room temperature. BALF samples col-
lected the day of necropsy were treated with 10 mM dithiothreitol
for 1 h at 37 ◦C to disrupt mucous and were assayed in triplicate
for each strain and for each antibody isotype (IgG or IgA). Optical
density (O.D.) readings were measured at 405 nm using an auto-
mated ELISA reader and the mean O.D. values were calculated for
each triplicate reading.
2.6. In vitro T-cell stimulation assays
Whole blood samples were collected in vacutainer cell prepa-
ration tubes with sodium citrate (CPTTM, BD Diagnostics, Franklin
Lakes, NJ) on 28, 49, 56, 70 dpv. Tubes were centrifuged at 1500 × g
for 30 min  at room temperature, and peripheral blood mononu-
clear cells (PBMCs) were collected. Remaining red blood cells were
lysed by adding 2 volumes of buffered water (deionized water with
0.15 M Na2HPO4 and 0.15 M KH2PO4) for 90 s followed by 1 volume
of 3× PBS. PBMC were pelleted, washed an additional time with
PBS, and resuspended in RPMI++ (RPMI 1640 with l-glutamine and
25 mM  HEPES), supplemented with 15% fetal bovine serum (Atlanta
Biologicals, Norcross, GA), penicillin (150 I.U./ml)/streptomycin
(150 g/ml)/amphotericin B (0.38 g/ml) solution (Mediatech, Inc.,
Herndon, VA), and 1.5 g/ml gentamicin (Invitrogen, Grand Island,
NY). Each PBMC suspension (106 cells in 200 L) was  dispensed
into multiple wells of a 96-well ﬂat-bottomed tissue culture plate.
One well received 50 L RPMI++ media as negative control. One
well received 50 L concanavalin A (25 g/mL) as a mitogen con-
trol. Other wells received 50 L each of live or UV-inactivated wild
type TX98 or live NS1126 TX98, each at a titer of 106 TCID50/mL.
Plates were incubated in 5% CO2 at 37 ◦C. After 4 days, PBMCs
were transferred to 96-well round-bottomed tissue culture plates
with 50 L protein transport inhibitor brefeldin A (BD Biosciences
Pharmingen, San Diego, CA) per well and incubated for an addi-
tional 4 h. PBMC were washed once with PBS++ (PBS with 0.5%
bovine serum albumin and 0.1% sodium azide). The primary anti-
body mix  for surface antigens (50 L) was added and incubated
at room temperature (RT) for 15 min. The primary antibody mix
consisted of mouse anti-swine CD4 (IgG2b), mouse anti-swine CD8
(IgG2a), mouse anti-swine  TCR (IgG1, directly conjugated with
ﬂuorescein isothiocyanate), and mouse anti-swine CD25 (IgG1,
directly conjugated with phycoerythrin) in PBS++. All monoclonal
antibodies were purchased from VMRD (Pullman, WA;  cat # 74-
12-4, 76-2-11, PGBL22A and PGBL25A, respectively) and titrated to
optimal dilutions for labeling. Direct conjugation of ﬂuorochromes
to monoclonal antibodies was performed by Chromaprobe (Mary-
land Heights, MO). PBMC were washed twice with PBS++ and
50 L of secondary antibody mix  was added to all wells and incu-
bated at RT for 15 min. The secondary antibody mix consisted of
goat anti-mouse IgG2b-PE-Cy-7 (cat# 1090-17, Southern Biotech,
Birmingham, AL) and goat anti-mouse IgG2a-PE-TR (cat# M32217,
Caltag Laboratories, Burlingame, CA) diluted in PBS++ at optimal
dilutions determined by titration (dilution factors are available
upon request). PBMC were washed 3 times with PBS++.
For intracellular staining, PBMC were incubated with 100 L BD
cytoﬁx-cytoperm solution (BD Biosciences Pharmingen) at RT for
30 min. The primary antibody mix  (50 L), consisting of rabbit anti-
swine IFN- (cat # AT-3072, MBL  International, Woburn, MA)  and
mouse anti-swine IL-10 biotin (IgG1, cat # 3075, MBL  International,
Woburn, MA)  in BD perm-wash solution, was  added to PBMC’s and
incubated at RT for 15 min, followed by 2 washes with BD perm-
wash solution. The secondary antibody reagent mix, consisting of
goat anti-rabbit IgG-AF700 (Alexa Fluor 700, cat# A21038, Invit-
rogen) and streptavidin-PerCP-Cy5.5 (cat# 551419, BD Biosciences
Pharmingen) in BD perm-wash solution, was  added and incubated
at RT for 15 min. Plates were washed 3 times with BD perm-wash
solution. A 1% solution of ultrapure formaldehyde (Polyscience,
Warrington, PA) in PBS (250 L) was  added to all wells followed by
transfer of treated cells to ﬂow tubes (Falcon, BD Labware) and kept
in the dark at 4 ◦C until ﬂow cytometric analysis. The FACSCanto
cytometer (BD Biosciences, San Jose, CA) was used to analyze the
samples at the Flow Cytometry Facility, Iowa State University. Data
were collected from at least 10,000 live cells per sample, based on
light scatter properties and were analyzed using FlowJo software
(Tree Star Inc, Ashland, OR). Four T-cell subsets were deﬁned by
surface markers as follows: CD4+CD8– TCR–, CD4+CD8+ TCR–,
CD4–CD8+ TCR–, and CD4–CD8– TCR+. Expression indices (EI)
were calculated for the CD25, IFN-, and IL-10 responses of virus
antigen-stimulated T-cell subsets. Each EI was computed, using
CD25 as the target for example, (%CD25 positive cells × geomet-
ric mean ﬂuorescence intensity) for cells stimulated with virus,
divided by the same target for control media-treated cells of the
same T-cell subset of the same animal.
2.7. Cytokine analysis
A 1 ml  aliquot of BALF was centrifuged at 300 × g for 10 min  at
4 ◦C to pellet cellular debris. The cell-free BALF was  used to assay
for levels of IL-1, IL-8, IL-6, TNF-, IL-2, IL-4, IL-12p70, IFN-,
and IL-10 by SearchLight multiplex ELISA performed according to
the manufacturer’s recommendations (Aushon Biosystems, Biller-
ica, MA). The average of duplicate samples for each sample was
used for statistical analysis.
2.8. Statistics
Lung lesion scores, log2-transformed HI titers, and log10-
transformed viral titers data were analyzed using a mixed linear
model for repeated measures (Proc Mixed, SAS for Windows,
Version 9.2, SAS Institute Inc., Cary, NC, USA). Covariance struc-
tures within pigs across time were tested and modeled using the
REPEATED statement to determine the optimal covariance struc-
ture. Linear combinations of the least squares means estimates
were used in a priori contrasts after testing for a signiﬁcant (p < 0.05)
treatment group effect. Comparisons were made between each
group at each time-point using a 5% level of signiﬁcance (p < 0.05)
to assess statistical differences. Cytokine concentrations were ana-
lyzed by one-way ANOVA in JMP  software (SAS Institute, Cary,
M.A. Kappes et al. / Vaccine 30 (2012) 280– 288 283
Fig. 1. Nasal shedding of virus following primary immunization. Nasal swabs col-
lected 2, 4, and 6 days after inoculation with wild type TX98 (H3N2), NS1126 TX98,
or  sham inoculum were titrated by infectivity on MDCK cell monolayers. Titers were
computed from results of replicate dilutions by the Reed–Muench method. Values
are reported as group mean ± SE.
NC) and isotype ELISA data were analyzed by two-way ANOVA
(v5.04 GraphPad Prism, La Jolla, CA). Where ANOVA showed signif-
icant differences among groups, the Tukey post-test was applied
for pairwise comparisons. In vitro T-cell EI values were natural
log-transformed and analyzed by repeated measures ANOVA and
controlled pairwise comparisons, using the Glimmix procedure
in SAS. Data from 49 and 56 dpv assays (representing secondary
responses immediately preceding challenge infection) were pooled
as a single prechallenge data point for the repeated measures anal-
ysis.
3. Results
3.1. Vaccine virus replication in naïve pigs
TX98 mutants with truncated NS1 replicated much less exten-
sively in the upper respiratory tract than wild type TX98 (Fig. 1). The
wild type virus, administered intranasally, replicated sufﬁciently
to produce nasal swab viral titers of approximately 104 TCID50/ml
through day 4. The mean titer dropped below 10 TCID50/ml  on day
6. In pigs vaccinated with the attenuated NS1126 TX98 mutant,
the mean viral titers did not exceed 10 TCID50/ml  on days 2 or 4, and
no virus was detected on day 6. This disparity in wild type TX98 and
NS1126 TX98 replication in vivo is consistent with the attenuated
phenotype in previously reported results [17].
3.2. Immune responses to vaccine or primary infection
Hemagglutination inhibition titers indicated that pigs serocon-
verted in response to NS1126 TX98 vaccination, but were below
the conventional protective threshold of 40 HI units (Fig. 2A).
Whereas the wild type TX98 elicited geometric mean HI titers
greater than 80 at day 14 and thereafter, the geometric mean HI
titers of NS1126 TX98 vaccinates peaked at 20 HI Units. The neg-
ative control group had no detectable HI antibodies throughout the
study. Therefore, while NS1126 TX98 elicited only modest lev-
els of HI antibody, the results demonstrate measurable peripheral
antibody responses to the vaccine.
While the wild type TX98 immunization did generate signif-
icantly higher serum HI antibody titers, antibody isotype ELISAs
performed with BALF samples demonstrated no statistical differ-
ence between the NS1126 TX98 and the wild type TX98 groups
irrespective of isotype (IgG or IgA) or antigen (TX98 or IA04)
(Fig. 2B). These data indicate that, at least in lungs, NS1126 TX98
vaccine elicited a mucosal antibody response equivalent to that
Fig. 2. Antibody response to vaccination. (A) Geometric mean serum hemaggluti-
nation inhibition (HI) titers against the H3N2 vaccine backbone, TX98, in samples
collected through the day of heterologous challenge infection (d65). HI titration was
performed with turkey red blood cells, beginning with a 10-fold dilution of serum.
No  positive titers were measured from the non-vaccinated control animals. The
wild type TX98 treatment group was statistically different from all other treatment
groups starting on day 14 post vaccination and continuing throughout the end of the
study (p < 0.01). (B) BALF collected at time of necropsy [5 dpi, 70 dpv] was assayed
in  triplicate for levels of inﬂuenza speciﬁc IgG and IgA antibodies against puriﬁed
whole virus antigens, either homologous TX98 or heterologous IA04 (H1N1). Values
are  reported as group mean ± SE O.D. values for each treatment group.
induced by wild type TX98 virus, including comparable levels of
cross-reactive antibodies to the H1N1 virus.
We  monitored induction of CMI  after vaccination by in vitro T cell
stimulation assays. Flow cytometry was used to measure changes in
cell surface expression of the activation marker CD25 (IL-2 receptor
-chain) and the production of the cytokines interferon- (IFN-)
and interleukin-10 (IL-10) in cells isolated from peripheral blood.
As with the serological data, results of these assays indicate an
increase in magnitude of T cell priming following wild type TX98
inoculation compared to NS1126 TX98 (Fig. 3). Antigen-driven
CD25 upregulation of all four major T cell subsets was low-to-
undetectable after vaccination with NS1126 TX98 and before
virus challenge (Fig. 3A). Wild type TX98 inoculation, in contrast,
primed for statistically signiﬁcant increases in CD25 responses of
CD4+CD8+ T cells on day 28. In the time period that immediately
preceded heterosubtypic challenge (day 46/56), the wild type TX98
group continued to show a statistically signiﬁcant increase in CD25
EI in all subsets except CD4+CD8– cells.
However, intracellular IFN- data from day 28 demonstrate that
an antigen-speciﬁc T-cell response was primed by NS1126 TX98
vaccination. For all four subsets of T cells, elevated virus-speciﬁc
IFN- responses were statistically signiﬁcant in groups primed with
NS1126 TX98 or wild type virus (Fig. 3B). Later, in the day 49/56
time period, only pigs primed with wild type virus had signiﬁcant
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Fig. 3. Flow cytometry-based analyses of T-cell priming. Pigs were immunized on day 0, with either wild type TX98 (H3N2), NS1126 TX98, or a sham inoculum. PBMC were
isolated  early after immunization (day 28), twice in the period immediately before challenge (day 49 and day 56), and 5 days after heterologous H1N1 challenge with IA04
(day  70). PBMC were dispensed into tissue culture plates with live TX98 (H3N2) virus or media alone, and incubated for 4 days, concluding with 4 h of Brefeldin A treatment.
T  cells were ﬂuorescently labeled with antibodies speciﬁc to subset markers CD4, CD8, and  TCR; activation marker CD25; and intracellular cytokines IFN- and IL-10.
Expression indices were calculated for CD25 (A), IFN- (B), and IL-10 (C), as described in Section 2. Horizontal bars marked with one or two  asterisks denote statistically
signiﬁcant differences between groups (*p < 0.05; **p < 0.001). Values are reported as group mean ± SE.
IFN- recall response (CD4+CD8+ and  T-cell subsets). Wild type
TX98 inoculation primed for a modest increase in intracellular IL-
10 levels in  TCR+ cells, but NS1126 TX98 vaccination did not
(Fig. 3C).
3.3. Heterosubtypic challenge
Pigs in all three treatment groups were challenged with the
H1N1 isolate IA04, differing in subtype of both major glycoproteins
as compared to TX98. Thus, the challenge virus was heterosubtypic
to the vaccine strain in regard to surface glycoproteins, but inter-
nal genes of the two strains had higher similarity. The predicted
amino acid sequence identities between TRIG segments of these
two viruses were >90%, whereas HA and NA identities were con-
siderably lower (40–50%) (Supplemental Table 1). Shedding of the
heterosubtypic challenge virus was monitored in nasal swabs col-
lected 3 and 5 days post-infection. At 3 days post-infection (dpi),
nasal swab virus titers were approximately 103 TCID50/ml, regard-
less of the vaccine treatment group (Fig. 4A). The lack of early
protection against replication in vaccinated animals was expected,
given the difference in subtype between vaccine and challenge
strains. By 5 dpi, however, there were signiﬁcant differences in
virus titers among vaccine treatment groups (Fig. 4B). In pigs
given the sham inoculation with no SIV antigen, nasal swab titers
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Fig. 4. Viral shedding after heterologous H1N1 virus challenge. Sixty-ﬁve days after primary immunization, all treatment groups were inoculated intranasally with IA04.
Nasal  swabs were collected at 3 and 5 days post infection. BAL ﬂuid was  collected from lungs at necropsy (day 5). Each specimen was titrated by infectivity on MDCK cell
monolayers. Titers were computed from results of replicate dilutions by the Reed–Muench method. Log10-transformed data were analyzed by one-way ANOVA and the Tukey
HSD  test for pairwise comparisons. Horizontal bars linking two  treatment groups denote statistically signiﬁcant differences in mean titer between groups (p < 0.05).
remained approximately 104 TCID50/ml. In contrast, very little virus
was detectable in pigs that had been primed by wild type H3N2
virus inoculation. Virus shedding by NS1126 TX98 vaccinated
pigs at 5 dpi was intermediate; almost 100 fold lower than in the
non-vaccinated controls. Virus was also titrated in BALF samples
collected upon necropsy at 5 dpi (Fig. 4C). By this parameter there
was an even greater disparity between non-vaccinated animals and
those that had been immunologically primed with attenuated or
wild type TX98. The mean BALF titer in the naïve group exceeded
105 TCID50/ml, signiﬁcantly different from the mean titers in both
groups with prior heterosubtypic immunity, which were between
101 and 102 TCID50/ml. In contrast to nasal swab titers, 5 dpi
BALF titers did not show a difference in protection between groups
primed with wild type TX98 versus attenuated NS1126 TX98.
Groups immunized with NS1126 TX98 or wild type TX98 did
not have reduced lung lesions after heterologous IA04 challenge
(5 dpi), compared with the non-vaccinated group. Mean macro-
scopic lesion scores (percentage of surface area ± standard error)
of the non-vaccinated, NS1126 TX98, and wild type TX98 groups
after challenge were 5.6 ± 0.7, 9.5 ± 0.8, and 12.1 ± 2.6, respectively.
The difference between non-vaccinated and wild type TX98 groups
was statistically signiﬁcant (p = 0.021), but the NS1126 TX98
group’s mean score was intermediate between the two, and not
signiﬁcantly different from either of them. Lung sections examined
by histology showed no statistically signiﬁcant difference between
the microscopic lung lesion scores of non-vaccinated (1.59 ± 0.24),
NS1126 TX98 (1.72 ± 0.31), and wild type TX98 (1.63 ± 0.46)
groups (Supplemental Fig. 1).
3.4. BALF cytokine levels after challenge
T cell-associated cytokines were analyzed in BALF samples col-
lected 5 days following heterosubtypic challenge (Fig. 5). The levels
of interleukin-2 (IL-2) and TNF- were moderately but signiﬁ-
cantly higher in the group primed with wild type TX98 than in
the non-vaccinated or NS1126 TX98 groups. The difference was
more pronounced in terms of IFN-, as pigs primed with wild type
TX98 had 4–5 times higher levels than pigs in the other groups.
There were no signiﬁcant differences in IL-10 protein concentra-
tions among groups in BALF post-challenge.
3.5. Antigen-speciﬁc T cell responses following heterosubtypic
challenge infection
We  collected PBMC from pigs a ﬁnal time at 5 dpi (70 dpv)
and assayed T cells for in vitro activation and cytokine secretion
Fig. 5. Cytokine detection in bronchoalveolar lavage ﬂuid samples of pigs 5 days post IA04 (H1N1) challenge infection. Cytokines were assayed by multiplex ELISA. The average
of  duplicate samples for each pig were used for statistical analysis. Statistical analysis was by one-way ANOVA and the Tukey test for pairwise comparisons. Horizontal bars
linking two  treatment groups denote statistically signiﬁcant differences between groups (p < 0.05).
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in response to wild type TX98 stimulation. The IFN- data from
Day 70 suggested a modest anamnestic response by CD4+CD8– and
 T-cells of pigs initially exposed to wild type TX98 (Fig. 3B).
Heterologous challenge did not lead to a measurable rise in the
IFN- response of the CD4+CD8+ T cells. However, the most notable
change in in vitro recall responses of T cells after challenge was
in the CD25 expression index of CD4+CD8+ cells. Prior to hetero-
subtypic challenge, this response was only statistically signiﬁcant
in the wild type TX98-primed treatment group. After challenge,
CD4+CD8+ T cells from the NS1126 TX98 group showed an
abrupt anamnestic increase in virus-stimulated CD25 expression
compared with corresponding T cells from the non-vaccinated
group (Fig. 3A). This indicates the NS1126 TX98 vaccine induced
a CD4+CD8+ T cell memory response, despite the absence of
detectable levels in pre-challenge peripheral blood samples.
4. Discussion
Multiple molecular strategies have been developed in recent
years for the design of live-attenuated inﬂuenza A vaccine can-
didates. NS1 deletion or truncation attenuates an inﬂuenza virus
by reducing its ability to antagonize the type I IFN response [28].
It was hypothesized that this class of mutant viruses would elicit
robust adaptive immune responses, despite attenuated replica-
tion, because restraints on the early innate response would be
relaxed. Indeed, viruses with deleted or truncated NS1 have been
shown to protect against virulent challenge in mice and pigs
[20,29]. A recent study investigated adaptive immune responses
in mice given intranasal inoculation with H1N1 strain A/Puerto
Rico/8/1934 (PR8) mutated by deletion or truncations of NS1 [30].
In that study, even the most attenuated (NS1 deletion mutant,
which did not replicate to a detectable level) and intermediately
attenuated (126 amino acids, equal in length to our TX98 NS1126)
mutant viruses elicited long-term systemic T- and B-cell responses,
including CD8 T cells that expanded after secondary challenge.
There appear to be parallels between those observations in mice
and our observations in pigs immunized with a similar NS1126
TX98 construct. In both models, only very low levels of vaccine
virus replication were detectable in the days following intranasal
inoculation, and serum HI antibody responses were lower than
those induced by wild type virus. Nonetheless, in both models
the vaccines primed antigen-speciﬁc T cells, whose numbers were
sharply elevated upon subsequent infection of the host. Pigs receiv-
ing intranasal NS1126 TX98 also had inﬂuenza-speciﬁc IgA and
IgG in BALF; these mucosal antibody levels were indistinguishable
from levels in pigs primed with wild type TX98.
In general, we observed greater T-cell priming in pigs immu-
nized with wild type TX98 infection than in pigs given the
attenuated NS1126 TX98 vaccine, especially in terms of CD25
and IFN- expression. Cytokine analysis of BALF samples after
H1N1 challenge also suggests that more T cells producing Th1-
type cytokines were present in lungs of pigs primed with wild
type TX98. Consistent with these immunological data, the nasal
shedding of heterosubtypic H1N1 challenge virus was  controlled
more rapidly in wild type TX98-primed animals, although the two
groups had similar low viral loads in the BALF. Although the wild
type TX98 group had the greatest heterologous protection in terms
of viral shedding, possibly due to T-cell memory, it also had the
highest macroscopic lung lesion scores at necropsy. Conversely,
pigs given the sham vaccine had much higher lung viral titers
than other groups, but signiﬁcantly lower macroscopic lung lesion
scores. It has been recognized that cellular immune mediators in
lungs can cause collateral tissue damage in the process of clearing
viral infections (reviewed by Bruder et al. [31]). In this study, sig-
niﬁcantly elevated levels of TNF-, IL-2 and IFN- were measured
in the BALF of the wild type TX98 treatment group as compared
to the non-vaccinated controls. The elevated cytokine data and
increased lung pathology resulting from the more reactive immune
response primed by wild type TX98 infection may  indicate a trade-
off between protection and pathology in the inﬂuenza infected
hosts.
In our study, immunization with live or attenuated virus primed
both the CD4+CD8– and CD4+CD8+ T-cell populations for early
IFN- recall responses. In subsequent assays, prior to challenge,
these IFN- responses leveled off or declined. After heterologous
challenge the characteristic recall responses of these two CD4+
populations became noticeably different, as CD4+CD8+ cells shifted
to a proﬁle of strong CD25 upregulation and low IFN- secre-
tion. This is consistent with the established properties of porcine
CD4+CD8+ T cells, which are unique compared to other mammalian
hosts in their high frequency outside the thymus [32]. The porcine
CD4+CD8+ population contains memory T helper cells that rec-
ognize antigens in an MHC  class II-restricted manner [33]. The
CD4+CD8+ are multifunctional, as they express perforin and medi-
ate antigen-speciﬁc cytolytic activity against virus-infected target
cells [34,35].  It is not clear why the CD4+CD8+ CD25 EI responses
of animals vaccinated with NS1126 TX98 remained low prior to
challenge. One possibility is that the wild type TX98 recall antigen
suppressed in vitro activation of quiescent memory cells. However,
we also tested recall responses in vitro with UV-inactivated TX98
and NS1126 TX98 viruses, and observed very similar CD25 and
intracellular cytokine proﬁles (data not shown). A more plausible
explanation is that these double-positive cells localized preferen-
tially to lymphoid tissues in non-infected animals and were not
detectable in the periphery until after challenge.
The recall response of CD4+CD8+ cells after challenge included
an upregulation in CD25 expression, indicative of cell activation,
but not an increase in the number of IFN- or IL-10 producing
cells. This represented a change from CD4+CD8+ cells at Day 28,
when the NS1126 TX98 and wild type TX98 groups had much
lower CD25 responses to re-stimulation, but statistically signiﬁcant
IFN- responses. These results suggest that the long-term memory
cells were uncommitted to either a Th1 or Th2 biased phenotype.
Such cells may  be comparable to the “central memory” T lympho-
cyte population, described in mice, which trafﬁc preferentially in
lymphoid tissues and are not committed to a Th1, Th2, or Th17
phenotype [36,37]. This would help explain their low frequency in
peripheral blood after pigs were immunized, followed by the sharp
rise after challenge.
Distinct lymphocyte trafﬁcking patterns might be partially
responsible for another surprising result, the minimal detection
of antigen-primed CD4–CD8+ T cells following immunization and
challenge. Porcine CD4–CD8+ T cells have been characterized as
classical cytotoxic T lymphocytes (CTL). One goal of developing
replicating inﬂuenza vaccine viruses, such as NS1126 TX98, is
to elicit CTLs through MHC  class I-restricted antigen presentation.
Future studies will test whether TX98 NS1126 primes CD4–CD8+
T cells that reside in secondary lymphoid organs or lungs. How-
ever, given the very low level of NS1126 TX98 virus detected in
pigs’ nasal swabs after intranasal inoculation, it is also possible that
the vaccine did not supply enough endogenous antigen to prime a
large population of CD4–CD8+ T cells. Viruses engineered with even
shorter NS1 proteins than that of NS1126 TX98 are paradoxically
less attenuated, in both pigs and mice [17,30].  It is reasonable to
predict that mutants such as those would elicit greater CD4–CD8+
T cell responses.
T-cell response data indicate that both NS1126 TX98 and
wild type TX98 induced antigen-speciﬁc  T cells. This included
intracellular IFN- and IL-10 recall responses, before and after het-
erosubtypic challenge. Porcine  T cells have not been extensively
characterized, but they can outnumber  T cells in the circulation
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of young pigs [38]. Antigen-speciﬁc memory  T-cell responses
were previously reported in pigs inoculated with porcine reproduc-
tive and respiratory syndrome virus [39]. The potential of  T cells
to protect against inﬂuenza infection is not known. In our study,
the treatment group with the greatest protection against hetero-
subtypic challenge, pigs primed with wild type TX98, also had the
most robust  T-cell responses, suggesting these cells may  have
had a protective role.
Previous work showed that intranasal NS1126 TX98 elicited
signiﬁcant IgG and IgA antibody titers in lungs, and the vaccine pro-
tected pigs against challenge with TX98 or a similar H3N2 strain
[21]. In that study, NS1126 TX98 vaccination conferred partial
protection against the heterosubtypic IA04 challenge. Our present
data provide insight into the cross-reactivity of T-cell epitopes in
the TX98 vaccine virus and IA04 challenge virus. The two  viruses
both contain internal proteins encoded by the TRIG cassette, while
HA and NA subtypes are mismatched (H3N2 versus H1N1). Chal-
lenge with IA04 appears to have triggered anamnestic responses
from T cells that had been primed by NS1126 TX98 or wild type
TX98 immunization (Fig. 3A). This is consistent with the concept
that many inﬂuenza T-cell epitopes occur in internal proteins and
are conserved between heterosubtypic viruses [40]. Our analyses of
T-cell priming after vaccination point to CD4+ T cell populations as
likely factors in NS1126 TX98 vaccine-induced cross-protection,
in addition to mucosal antibodies. The results show that highly
attenuated SIV vaccines derived by truncating NS1 are capable of
inducing broadly reactive cellular immunity and providing protec-
tion against strains with dissimilar surface antigens.
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